安科生物(300009.SZ)：参股公司PA3-17注射液获准进入关键性II期临床试验

Core Viewpoint - Anke Biotech (300009.SZ) announced that its affiliated companies, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the key Phase II clinical trial of PA3-17 injection, a targeted CAR-T cell therapy for adult relapsed and refractory CD7-positive hematological malignancies [1] Group 1 - The PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product to receive clinical trial approval [1] - The product utilizes advanced genetic engineering technology to modify the patient's own T cells, enabling them to specifically recognize and kill CD7-positive tumor cells [1] - The approval marks a significant milestone for Boshengji Anke in the development of innovative cancer therapies [1]